Drug Profile
Research programme: betulinol-based therapeutics - Marc Pharmaceuticals
Alternative Names: Betulinol-based therapeutics research programme - Marc PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Marc Pharmaceuticals
- Class Monoclonal antibodies; Triterpenes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections; Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 27 May 2005 Preclinical trials in Cancer in USA (unspecified route)